BWA
DYN icon

Basecamp Wealth Advisors’s Dyne Therapeutics DYN Stock Holding History

Basecamp Wealth Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$733 Hold
33
– – ﹤0.01% 1574
2026
Q1 		$598 Sell
33
-9
-21% -$155 ﹤0.01% 1678
2025
Q4 		$822 Buy
+42
New +$795 ﹤0.01% 1536

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Basecamp Wealth Advisors's DYN Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Dyne Therapeutics (DYN) position steady in Q2 2026 at 33 shares worth $733. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

Basecamp Wealth Advisors first reported a position in DYN in Q4 2025 and has held it in 3 quarters since. The position peaked at $822 in Q4 2025. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Basecamp Wealth Advisors held 33 shares of Dyne Therapeutics worth $733 as of Q2 2026.
  • Basecamp Wealth Advisors left its Dyne Therapeutics share count unchanged in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1574 holding.
  • Basecamp Wealth Advisors first reported a position in Dyne Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Dyne Therapeutics position peaked at $822 in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.